摘要
目的:调查和分析肿瘤患者产超广谱β-内酰胺酶(ESBLs)大肠埃希菌感染的临床分布和耐药性,为临床用药和控制医院感染提供科学依据。方法:回顾性调查我院2014-01—2016-12分离的产ESBLs大肠埃希菌临床资料,分析其临床分布和耐药性情况。结果:共计培养出大肠埃希菌103株,其中产ESBLs大肠埃希菌69株,其检出率为67.0%;在年份、性别、年龄、感染部位、感染类别等分布中,产ESBLs大肠埃希菌检出率差异无统计学意义;在肿瘤种类分布中,消化系肿瘤患者产ESBLs大肠埃希菌检出率高于泌尿生殖器肿瘤患者(P=0.001)和其它部位肿瘤患者(P=0.010);在标本分布中,引流液标本产ESBLs大肠埃希菌检出率高于血标本(P=0.0027);产ESBLs菌株对多种临床常用抗菌药物的耐药率均高于非产ESBLs菌株,耐药率多在60%以上,对碳青霉烯类抗菌药物普遍敏感。结论:肿瘤患者产ESBLs大肠埃希菌检出率和耐药性均较高,应加强监测,合理使用抗菌药物,以预防和控制产ESBLs大肠埃希菌感染。
Objective： To investigate the clinical distribution and drug resistance of extended-spectrum β-lactamase（ESBLs）-producing Escherichia coli in tumor patients so as to provide a scientific basis for clinical use of antibiotics and control of nosocomial infections. Methods： The clinical data of ESBLs-producing E. coli strains isolated from Jan 2014 to Dec 2016 were retrospective investigated, the clinical distribution and drug resistance were analyzed. Result： From Jan 2014 to Dec 2016, a total of 103 strains of E. coli had been isolated, among which there were 67 strains of ESBLs-producing strains, the detection rate was 67.0%.There was no statistical significance in the detection rate of ESBLs-producing strains among the distribution of years, sexes, ages, infection sites and infection categories（P〈0.05）.In the distribution of tumor types, the detection rate of ESBLs-producing strains in gastrointestinal tumors patients was higher than that in urogenital tumors（P=0.001） and other tumors patients（P=0.010）. In the distribution of specimens, the detection rate of ESBLs-producing strains in drainage fluid was higher than that in blood（P=0.0027）. The drug resistance rates of ESBLs-producing strains to commonly used antimicrobial agents were higher than that of non-ESBLs-producing strains. Most of the drug resistance rates were over 60%. The ESBLs-producing strains were sensitive to carbapenem antibiotic. Conclusion： Both of the detection rate and the drug resistance rate of ESBLs-producing E. coli strains in tumor patients were relatively high. It is necessary to strengthen the monitoring of drug resistance and reasonably use of antibiotic so as to prevent and control the infection cause by ESBLs-producing E. coli strains.
作者
蔡奋
张庆英
蔡晓锐
彭裕辉
许镒洧
江敏霞
CAI Fen;ZHANG Qing-ying;CAI Xiao-rui;PENG Yu-hui;XU Yi-wei;JIANG Min-xia(Department of Nosocomial Infection Prevention and Control, Cancer Hospital of Shantou University Medical College;Department of Public Health and Preventive Medicine, Shantou University Medical College;Department of Pharmacy, Cancer Hospital of Shantou University Medical College;Department of Clinical Laboratory, Cancer Hospital of Shantou University Medical College, Shantou 515041, China)
出处
《汕头大学医学院学报》
2018年第2期89-92,共4页
Journal of Shantou University Medical College
关键词
肿瘤患者
超广谱Β-内酰胺酶
大肠埃希菌
临床分布
耐药性
tumor patients
extended-spectrum β-lactamase（ESBLs）
escherichia coli
clinical distribution
drug resistance
